Suppr超能文献

肾素-血管紧张素系统三联阻断对肾移植后复发性局灶节段性肾小球硬化的影响。

Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.

作者信息

Freiberger Verena, Amann Kerstin, Heemann Uwe, Frank Helga

机构信息

Department of Nephrology, Klinikum rechts der Isar, Technische Universitaet Muenchen, Munich, Germany.

出版信息

Transpl Int. 2009 Nov;22(11):1110-3. doi: 10.1111/j.1432-2277.2009.00897.x. Epub 2009 May 20.

Abstract

Recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation with nephrotic syndrome is a serious problem with a high risk of graft loss. The therapeutic role of renin-angiotensin-system (RAS) blockers in recurrent FSGS is not clear. We present the safety and efficacy of an intensified triple RAS blockade with an ACE-inhibitor, an AT 1 receptor blocker and the direct renin inhibitor aliskiren in a 29-year-old renal transplant recipient with biopsy proven recurrence of FSGS and relapsing severe nephrotic syndrome. We subsequently used full dose ramipril, candesartan and aliskiren under a close monitoring of kidney function and electrolytes and examined the effect on proteinuria, clinical course and tolerability over 12 months. We found a significant and sustained antiproteinuric effect under triple RAS blockade. RAS blockade was generally well tolerated. This can offer a new therapeutic approach in selected hypertensive patients with recurrent FSGS.

摘要

肾移植后复发性局灶节段性肾小球硬化(FSGS)伴肾病综合征是一个严重问题,移植肾丢失风险高。肾素-血管紧张素系统(RAS)阻滞剂在复发性FSGS中的治疗作用尚不清楚。我们报告了一名29岁肾移植受者强化三联RAS阻断治疗的安全性和有效性,该受者经活检证实为FSGS复发且肾病综合征复发严重,使用了一种血管紧张素转换酶抑制剂、一种AT1受体阻滞剂和直接肾素抑制剂阿利吉仑进行强化三联RAS阻断。随后,我们在密切监测肾功能和电解质的情况下使用了全剂量雷米普利、坎地沙坦和阿利吉仑,并在12个月内检查了对蛋白尿、临床病程和耐受性的影响。我们发现三联RAS阻断下有显著且持续的抗蛋白尿作用。RAS阻断总体耐受性良好。这可为选定的复发性FSGS高血压患者提供一种新的治疗方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验